Movement monitoring in ALS patients
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study uses a wearable device to track movement patterns in people with ALS. It aims to better understand how the disease affects movement over time, which may help improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of ALS (definite or probable).
- You are at least 18 years old.
- You are willing to sign a consent form.
- If you take Riluzole, your dose has been steady for at least 1 month and will not change during the study.
- You do not have major thinking or communication problems that would make it hard to follow instructions.
- You have not had recent surgery or injury to your arms or legs in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study continuously measures activity and movement in people with ALS and in control participants. It aims to better understand how muscle disease changes day-to-day function, which may help improve future monitoring or care.
This study follows people with ALS and healthy volunteers to measure how specific body fluids, symptoms, and at-home tracking change over time. It may help researchers find early signs of disease changes and better ways to measure treatment effects.
This study uses smartphone apps and digital tools to track physical changes in people with ALS. It aims to better understand how the disease affects daily function, which could help improve future care.
This study measures how well your nerves and muscles work together to see if it can serve as an early sign (a “biomarker”) of ALS. It may help doctors track ALS more accurately, especially in people who already seem to have ALS based on nerve testing.
This study tests a device called Myolex mScan that measures muscle health non-invasively in people with ALS. It aims to see if this can be a useful biomarker to track the disease progression.
This study uses MRI brain scans to understand how ALS affects the brain over time. It may help researchers develop better ways to measure the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.